ARSN 611 819 651 | APIR WHT0066AU | mFund SPM01

Performance as at 31 March 2023

	1 Month	3 Months	1 Year	3 Years p.a.	5 Years p.a.	Inception p.a ¹
Fund ²	0.8%	3.3%	-7.5%	35.6%	11.4%	13.1%
Benchmark ³	-0.7%	1.9%	-13.2%	13.2%	3.9%	6.0%
Difference	1.6%	1.4%	5.7%	22.4%	7.5%	7.1%
Microcap Index ^a	-0.3%	2.4%	-20.9%	33.0%	9.1%	10.2%

¹ Inception date is 16 May 2016. Past performance is not a reliable indicator of future performance. All p.a. returns are annualised.

² Spheria Australian Microcap Fund. Returns of the Fund are net of applicable fees, costs, and taxes.

³ Benchmark is the S&P/ASX Small Ordinaries Accumulation Index.

^a Microcap Index refers to S&P/ASX Emerging Companies Accumulation Index.



Overall Commentary


The Spheria Australian Microcap Fund returned 0.8% (after fees) during the month of March, outperforming the S&P/ASX Small Ordinaries Accumulation Index by 1.6%.

Top 5 Holdings


Company Name	% Portfolio
Supply Network Limited	4.4
Appen Limited	4.4
Mader Group Limited	4.3
Bravura Solutions Limited	4.3
Vista Group International Limited	4.2
Тор 5	21.5

Market Cap Bands

Source: Spheria Asset Management



Active Sector Exposure



Source: Spheria Asset Management



Spheria Australian Microcap Fund

ARSN 611 819 651 | APIR WHT0066AU | mFund SPM01

Markets

The small-cap and mid-small indices both fell again over March on account of concerns around the economy and the possibility of financial contagion after three US banks – led by Silicon Valley Bank - failed. The decline in the Australian Dollar and a sense that interest rates may be close to peaking looks to have prompted a re-emergence in corporate activity. Invocare (IVC.ASX) received a bid early in the month from private equity group TPG, followed later in the month by Liontown Resources (LTR.ASX) and then United Malt Group (UMG.ASX). Corporate activity is hard to predict, however we expect to see more as private equity and trade buyers capitalise on weak share price performance and attractive valuations. Whilst not an explicit consideration in our investment process, our focus on strong cash flow businesses with attractive balance sheets and valuations means that we tend to be outsized beneficiaries during periods of elevated M&A activity.

Major Contributors to Performance

Over the month the largest contributors to performance were Appen (APX.ASX, +22%), Vita Group (VTG.ASX, +62%) and Regis Healthcare (REG.ASX, +26%).

Vita Group (VTG.ASX) – share price rallied 62% in March after the company entered a Scheme Implementation Agreement (SIA) with Practice Management. Under the SIA Practice Management will acquire 100% of the issued shares of Vita Group for \$0.06255 cash and will allow VTG to pay a fully franked dividend of up to \$0.06425 per VTG share subject to the scheme being approved. The total value to VTG shareholders will be up to \$0.1268 per VTG (before the benefit of any franking credits) which represents a 59% premium to the undisturbed closing price. We sold some of our holding into the bid and since month end, we have exited the position.

Major Detractors from Performance

The largest detractors were *not owning* Liontown Resources (LTR.ASX, +90%), and overweight positions in Praemium (PPS.ASX, -13%) and Bravura Solutions (BVS.ASX, -42%).

Liontown Resources (LTR.ASX) – share price rose almost 90% in March, after the company received a takeover bid at the end of the month. Albemarle Corporation (Albemarle) is seeking to acquire 100% of the shares of LTR at a price of \$2.50, a 64% premium to the prior day's closing price. The mandate does not own LTR and hence it was a detractor from returns over the month. We have discussed our views on lithium over the last year as prices moved exponentially higher in 2022 on expectations of a multi-year supply deficit. We strongly believed that such prices were unsustainable, and this proved correct as pricing subsequently collapsed from a peak of US\$80,000/t (lithium carbonate) to approximately US\$/30,000 at the time of writing. Many of the lithium names (particularly the explorers and developers) came under intense selling pressure as a result, which clearly piqued Albermarle's interest. Whilst the bid hurts relative performance, we continue to remain disciplined in our investment approach and use mid-cycle (long-term) lithium price assumptions to value these companies.

Outlook & Strategy Going Forward

Smaller companies tend to get sold off more aggressively in downturns and risk-off markets. The past year has seen a large demarcation in performance between the larger cap index and smaller caps, domestically. As sentiment shifts, small caps have historically outperformed large caps as risk / return profiles adjust. The fact private equity and corporates are back active in the market indicates that value has truly emerged and is being snapped up by opportunistic and well-funded acquirors. We are starting to see investors attempting to predict where the next bid will come from with interest returning to names including Bega Cheese (BGA.ASX), Blackmores (BKL.ASX) and Iress (IRE.ASX). There are many uncertainties economically speaking but looking ahead over the next 12 months, we feel we are well positioned given our focus on fundamentals and cash generative businesses.



Spheria Australian Microcap Fund

ARSN 611 819 651 | APIR WHT0066AU | mFund SPM01

Platform Availability List

If a fund is not available on your preferred platform, please contact us. Please check with your platform for minimum investment requirements and fees

Aegis	FNZ Group	MLC Navigator	PowerWrap
Asgard	HUB24	MLC Wrap	Praemium
BT Panorama	IOOF eXpand	Netwealth	Premium Choice
DPM	Macquarie Wrap	OneVue	Wealth02 uXchange

Spheria Australian Microcap Fund	
Benchmark	S&P/ASX Small Ordinaries Accumulation Index
Investment Objective	The Funds aims to outperform the S&P/ASX Small Ordinaries Accumulation Index over the medium to long term
Investing Universe	Primarily listed companies outside the top ASX 250 listed companies by market capitalisation and companies listed on the New Zealand Stock Exchange with an equivalent market capitalisation
Holdings	Generally 20-65 stocks
Distributions	Annually
Fees	1.35% p.a management fee & 20% performance fee of the Fund's excess return versus its benchmark, net of the management fee
Cash	Up to 20% cash, typically 5% - 10%
Expected Turnover	20% - 40%
Style	Long only
APIR	WHT0066AU
Minimum Initial Investment	\$25,000



Spheria Australian Microcap Fund

ARSN 611 819 651 | APIR WHT0066AU | mFund SPM01

Fund Ratings



Fund Ratings

For more information, please contact Pinnacle Investment Management Limited on 1300 010 311 or email <u>distribution@pinnacleinvestment.com</u>

Disclaimer

This communication is prepared by Spheria Asset Management Pty Limited ('Spheria') (ABN 42 611 081 326, Corporate Authorised Representative No. 1240979) as the investment manager of the Spheria Australian Microcap Fund (ARSN 611 819 651) (the 'Fund'). Pinnacle Fund Services Limited ('PFSL') (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Funds. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund are available via the links below. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.

Link to the <u>Product Disclosure Statement</u> Link to the <u>Target Market Determination</u>

For historic TMD's please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Whilst Spheria, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Spheria, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Spheria and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Spheria. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

This may contain the trade names or trademarks of various third parties, and if so, any such use is solely for illustrative purposes only. All product and company names are trademarks[™] or registered[®] trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and Spheria.

Zenith Disclaimer: The Zenith Investment Partners ('Zenith') (ABN 27 103 132 672, AFSL 226872) rating (assigned Spheria Australian Microcap Fund – February 2022) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at https://www.zenithpartners.com.au/our-solutions/investment-research/fund-research-regulatory-guidelines/.

Lonsec Disclaimer: The Lonsec rating (assigned as follows: Spheria Australian Microcap Fund October 2022) presented in this document is published by Lonsec Research Pty Ltd ('Lonsec') (ABN 11 151 658 561, AFSL 421445). The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Affiliate Name products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: https://www.lonsec.com.au/investment-product-ratings/.